Bio-Rad Laboratories announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this role on December 31, 2019. Grantham Wright will be responsible for providing global leadership and management of the overall strategy and business direction for the company’s Clinical Diagnostics Group global operations.
“We are pleased to have Dara join Bio-Rad and believe she will make an excellent addition to our team,” said Andrew Last, Bio-Rad Executive Vice President and Chief Operating Officer. “Dara brings a wealth of experience, business acumen, and a proven track record of success that make her the ideal person to lead our Clinical Diagnostics Group. We would also like to thank John for his many years of valuable contributions to the growth and success of Bio-Rad, and we wish him the best in his retirement,” Dr. Last said.
Grantham Wright most recently was Vice President & General Manager, Biosciences Division, Life Science Solutions Group, Protein & Cell Analysis, Thermo Fisher Scientific, the company’s largest business unit. Prior to Thermo Fisher Scientific, she was Senior Vice President & General Manager, eBioscience Business Unit at Affymetrix.
Grantham Wright has also served with Boreal Genomics as Chief Commercial Officer and with Affymetrix as Global Vice President of Strategic Marketing & Clinical Applications. Prior to Affymetrix, she spent over 10 years in marketing roles at BD Biosciences.
Grantham Wright holds a Master’s Degree in Business Administration from San Diego State University and a Bachelor of Arts in Biology and Spanish.